Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study

D. Kamp(Utrecht University), Nadia Haj Mohammad(Utrecht University)

European Journal of Cancer

February 1, 2025

10.1016/j.ejca.2025.115278

Cited by 1

Related Papers

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)

|BMC Cancer|2019|111

Hepatic arterial infusion pump chemotherapy in patients with advanced intrahepatic cholangiocarcinoma confined to the liver: A multicenter phase II trial.

|Journal of Clinical Oncology|2024|12

Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma—PUMP-2 Trial

|Journal of Clinical Oncology|2025|5

Patient preference trials in oncology: a scoping review and recommendations on reporting

|Journal of Clinical Epidemiology|2025|1

Hepatic arterial infusion pump chemotherapy in patients with advanced intrahepatic cholangiocarcinoma confined to the liver: a multicenter phase II trial

|HPB|2024|0